Prothesendruckstellen als Risiko einer Bisphosphonat-assoziierten Kiefernekrose

Die Bisphosphonat-assoziierte Kiefernekrose stellt ein schwer zu therapierendes Krankheitsbild dar, welches zu einer deutlichen Verminderung der Lebensqualität führt. Im Rahmen auslösender Ereignisse sind Zahnextraktionen und chirurgische Eingriffe weitestgehend den Behandlern bekannt. Prothesendruckstellen werden jedoch in ihrer Relevanz häufig unterschätzt. In einer eigenen Untersuchung mit 195 Patienten mit Kiefernekrosen waren Prothesendruckstellen mit 26 % die zweithäufigste Ursache. Über entsprechende Erfahrungen mit diesen Patienten soll hier berichtet sowie mögliche Empfehlungen in Prophylaxe und Therapie diskutiert werden.

• Literatur

• 1 Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 2009; 67 (Suppl. 05) 61-70
• 2 Bamias A et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 2005; 23: 8580-8587
• 3 Döring K et al. Die Bisphosphonat-assoziierte Kieferosteonekrose. Oralchirurgie Journal 2007; 1: 26-30
• 4 Garrett NR et al. Effects of improvements of poorly fitting dentures and new dentures on patient satisfaction. J Prosthet Dent 1996; 76: 403-413
• 5 Göllner M et al. Prosthodontic treatment of a patient with bisphosphonate-induced osteonecrosis of the jaw using a removable dental prosthesis with a heat-polymerized resilient liner: a clinical report. J Prosthet Dent 2010; 103: 196-201
• 6 Hasegawa Y et al. Influence of dentures in the initial occurrence site on the prognosis of bisphosphonate-related osteonecrosis of the jaws: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 114: 318-324
• 7 Hoefert S, Eufinger H. Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 10: 463-469
• 8 Hoefert S et al. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin Oral Invest 2010; 14: 271-284
• 9 Hoff AO et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23: 826-836
• 10 Kivovics P et al. Frequency and location of traumatic ulcerations following placement of complete dentures. Int J Prosthodont 2007; 20: 397-340
• 11 Kyrgidis A et al. Bisphosphonate-related osteonecrosis of the jaws: a case control study of risk factors in breast cancer patients. J Clin Oncol 2008; 26: 4634-4638
• 12 Lo JC et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010; 68: 243-253
• 13 Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-1117
• 14 Okita N et al. In vivo and in vitro studies on soft tissue materials: microbial adhesion and tests for antibacterial activity. Dent Mater 1991; 7: 155-160
• 15 Pazianas M. Osteonecrosis of the jaws and the role of macrophages. J Natl Cancer Inst 2011; 103: 232-240
• 16 Reid IR et al. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxity?. Bone 2007; 41: 318-320
• 17 Ruggiero SL et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws – 2009 update. J Oral Maxillofac Surg 2009; 67: 2-12
• 18 Saad F et al. Incidence, risk factors, and outcome of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012; 23: 1341-1347
• 19 Stark H et al. Nachsorgestrategien für Zahnersatz. zm 2011; 101: 60-64
• 20 Suwattee P et al. Sunitinib: a case of bullous palmoplantar erythodysesthesia, periungual erythema, and mucositis. Arch Dermatol 2008; 144: 123-125
• 21 Toda M et al. Antibacterial and anti-hemolysin activities of tea catechins and their structural relatives. Nippon Saikingaku Zasshi 1990; 45: 561-566
• 22 Tripathi A et al. Bisphosphonate therapy for skeletal malignancies and metastases: Impact on jaw bones and prosthodontic concerns. J Prosthodontics 2011; 20: 601-603
• 23 Vahtsevanos K et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009; 27: 5356-5362
• 24 Vescovi P et al. Surgery-triggered and non surgery-triggered bisphosphonate-related osteonecrosis of the jaws (BRONJ): a retrospective analysis of 567 cases in an Italian multicenter study. Oral Oncology 2011; 47: 191-194
• 25 Walter C et al. Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients. Head & Face Medicine 2010; 6: 11-18
• 26 Yarom N et al. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 2007; 18: 1363-1370
• 27 007/091-Bisphosphonat-assoziierte Kiefernekrose (BP-ONJ) und andere medikamenten-assoziierte Kiefernekrosen. AWMFonline. Im Internet: http://www.awmf.org/uploads/tx_szleitlinien/007-091l_S3_Bisphosphonat-assoziierte_Kiefernekrose_2012-04.pdf Stand: 04/2012